TerminatedPhase 2NCT02029417
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Evelena Ontiveros, MD PhDRoswell Park Cancer Institute
- Intervention
- cytarabine(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2014 – 2015
Study locations (1)
- Roswell Park Cancer Institute, Buffalo, New York, United States
Collaborators
National Cancer Institute (NCI) · Teva Pharmaceutical Industries, Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02029417 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.